- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07940621
Inotuzumab Plus Venetoclax in Older or Unfit Patients With Newly Diagnosed BCR::ABL1-Negative B-ALL
Inotuzumab Ozogamicin Plus Venetoclax in Older Patients With Newly Diagnosed BCR::ABL1-Negative B-Cell Acute Lymphoblastic Leukemia Unfit for Chemotherapy: A Prospective Study
This multicenter, open-label, prospective clinical study aimed to preliminarily investigate the efficacy and safety of inotuzumab ozogamicin combined with venetoclax as induction therapy in older patients with newly diagnosed B-cell acute lymphoblastic leukemia who are unfit for chemotherapy.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 2 단계
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Newly diagnosed Ph/BCR::ABL1-negative B-cell acute lymphoblastic leukemia (B-ALL) according to the WHO 5th edition classification of haematolymphoid tumours;
- CD22 protein expression on the surface of leukemic blasts >20%, as confirmed by flow cytometry or immunohistochemistry on pathological tissue;
- The patient meets any one of the following conditions:
Age >65 years; Cardiac ejection fraction ≤50%, or very severe cardiovascular comorbidities such as refractory congestive heart failure; Diffusing capacity of the lung for carbon monoxide (DLCO) ≤65% or forced expiratory volume in 1 second (FEV1) ≤65%, or other severe pulmonary comorbidities; Child-Pugh class B/C cirrhosis or transaminases >3 times the upper limit of normal, or other severe hepatic comorbidities; The patient requires dialysis, or has other severe renal comorbidities; Active infection unresponsive to anti-infective therapy, or other severe infections; Psychiatric disorders requiring continuous specialized psychiatric treatment, or a dependent cognitive status that cannot be managed by the caregiver; ECOG performance status ≥3; Other uncontrolled malignancies; Unsuitability for multi-agent combination chemotherapy due to severe thrombocytopenia (<10×10^9/L), severe neutropenia/agranulocytosis (<0.5×10^9/L), or other reasons; The patient refuses multi-agent combination chemotherapy for personal or other reasons; Other comorbidities that, in the investigator's judgment, make the patient unsuitable for multi-agent combination chemotherapy;
- Voluntary participation in this trial and provision of signed informed consent.
Exclusion Criteria:
- Age <18 years;
- Diagnosis of mixed phenotype acute leukemia (MPAL), mature B-cell neoplasms (e.g., Burkitt lymphoma), or extramedullary disease at diagnosis;
- Philadelphia chromosome detected by bone marrow cytogenetic testing, BCR::ABL1 fusion gene detected by molecular testing of bone marrow/blood, or chronic myeloid leukemia in blast crisis;
- Hypersensitivity to inotuzumab ozogamicin or venetoclax;
- Prior confirmed severe or persistent hepatic veno-occlusive disease (VOD), or severe persistent liver disease;
- Requirement for life-support treatment, including vasopressors and invasive mechanical ventilation;
- Pregnancy or lactation;
- Any condition that, in the investigator's judgment, makes the patient unsuitable for enrollment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 개입 그룹
|
One induction cycle consisted of fixed-dose INO (1 mg on days 1, 8, and 15), VEN (100 mg on day -2, 200 mg on day -1, and 400 mg on days 0-20), and MP (1 mg/kg from days -2 to 11, followed by a 2-week taper) The intensity of consolidation therapy was determined by leukemia burden. Patients achieving CR with MRD positivity received INO (1 mg on day 1 and 8) and VEN (400 mg daily on day 1-14). Those attaining MRD negativity received INO (1 mg on day 1) plus VEN (400 mg daily on day 1-7) |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
overall response rate
기간: Till the end of the study, up to 24 months
|
Till the end of the study, up to 24 months
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
minimal residual disease negativity rate
기간: Till the end of the study, up to 24 months
|
Till the end of the study, up to 24 months
|
|
overall survival
기간: Till the end of the study, up to 24 months
|
Till the end of the study, up to 24 months
|
|
Relapse-free survival
기간: Till the end of the study, up to 24 months
|
Till the end of the study, up to 24 months
|
|
Hematological toxicity: neutropenia, thrombocytopenia, febrile neutropenia, anemia, bone marrow suppression Non hematological toxicity: SOS,TLS, peripheral edema, fever, fatigue, MODS, infection, liver dysfunction, renal dysfunction et al.
기간: Till the end of the study, up to 24 months
|
Till the end of the study, up to 24 months
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- SH-ALL 005
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .